Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.63 |
| ▸ | RECQL | P46063 | 3/20 | 0.63 |
| ▸ | USP2 | O75604 | 2/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.63 |
| ▸ | HTR2A | P28223 | 2/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.63 |
| ▸ | LCK | P06239 | 2/20 | 0.63 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | FYN | P06241 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | KDM6B | O15054 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 5/20 | 0.58 |
| ▸ | CA2 | P00918 | 5/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15221364 | 1.00 | KDM4E (0.63) | KDM4EALOX15HSD17B10HIF1ATDP1 | |
| SCHEMBL30287608 | 1.00 | KDM4E (0.63) | KDM4EALOX15HSD17B10HIF1ATDP1 | |
| Water SCHEMBL28760502 | 0.98 | KDM4E (0.61) | KDM4EALOX15HSD17B10HIF1ATDP1 | |
| SCHEMBL12535931 | 0.87 | KDM4E (0.59) | KDM4EALOX15HSD17B10HIF1ATDP1 | |
| SCHEMBL30724831 | 0.86 | KDM6B (0.64) | KDM4EALOX15HSD17B10HIF1ATDP1 | |
| SCHEMBL29429645 | 0.85 | KDM6B (0.62) | KDM4EALOX15HSD17B10HIF1ATDP1 | |
| SCHEMBL5063603 | 0.85 | KDM6B (0.62) | KDM4EALOX15HSD17B10HIF1ATDP1 | |
| SCHEMBL29669984 | 0.85 | KDM6B (0.62) | KDM4EALOX15HSD17B10HIF1ATDP1 | |
| SCHEMBL15117440 | 0.84 | KDM4E (0.56) | KDM4EALOX15HSD17B10HIF1ATDP1 | |
| SCHEMBL27315605 | 0.84 | KDM4E (0.59) | KDM4EALOX15HSD17B10HIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220298-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING METABOLIC SYNDROME INDUCED BY ANTIPSYCHOTIC TREATMENT AND RELATED DISEASES AND CONDITIONS | TUFTS MEDICAL CENTER, INC. | 2021-07-22 | — | — | US | claimed |
| WO-2021216781-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3876871-A1 | SMALL MOLECULE DRUGS AND METHODS TO ACCELERATE OSSEOINTEGRATION | The Regents of the University of California (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20210220298-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING METABOLIC SYNDROME INDUCED BY ANTIPSYCHOTIC TREATMENT AND RELATED DISEASES AND CONDITIONS | TUFTS MEDICAL CENTER, INC. | 2021-07-22 | — | — | US | disclosed |
| WO-2019040527-A1 | DOPA FORMULATIONS FOR TREATMENTS OF PARKINSON'S DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-02-28 | — | — | WO | disclosed |
| US-20180055800-A1 | Pulmonary Delivery for Levodopa | CIVITAS THERAPEUTICS INC (US) | 2018-03-01 | — | — | US | disclosed |
| US-20170196828-A1 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same | NEURODERM, LTD. (IL) | 2017-07-13 | — | — | US | disclosed |
| US-20170196828-A1 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same | NEURODERM, LTD. (IL) | 2017-07-13 | — | — | US | disclosed |
| US-20130253056-A1 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same | NEURODERM, LTD. (IL) | 2013-09-26 | — | — | US | disclosed |
| US-20130253056-A1 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same | NEURODERM, LTD. (IL) | 2013-09-26 | — | — | US | disclosed |
| US-4170654-A | Antihypertensive compositions containing N-heterocyclicalanines and α- | MERCK & CO., INC. (US) | 1979-10-09 | — | — | US | disclosed |
| US-4160835-A | Antihypertensive compositions containing an arylsubstituted alanine and a phenyl hydrazinopropionic acid | MERCK & CO., INC. (US) | 1979-07-10 | — | — | US | disclosed |
| US-4156734-A | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid | MERCK & CO., INC. (US) | 1979-05-29 | — | — | US | disclosed |
| US-4069333-A | 2-HYDRAZINO-3-PHENYLPROPIONIC ACID DECARBOXYLASE INHIBITORS, BENZOXAZOLE ANALINES | MERCK & CO., INC. (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220298-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING METABOLIC SYNDROME INDUCED BY ANTIPSYCHOTIC TREATMENT AND RELATED DISEASES AND CONDITIONS | GPR119, PC, NLN | KDM4E 3272/4885ALOX15 1279/4885HSD17B10 381/4885 |
| US-20170196828-A1 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same | COMT, SNCA, SCLY | KDM4E 2284/4885ALOX15 806/4885HSD17B10 1176/4885 |
| US-20130253056-A1 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same | COMT, SNCA, SCLY | KDM4E 2284/4885ALOX15 806/4885HSD17B10 1176/4885 |
| US-20180055800-A1 | Pulmonary Delivery for Levodopa | PARK7, SNCA, COMT | KDM4E 3816/4885ALOX15 1454/4885HSD17B10 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.